High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 38: | Line 38: | ||
|- | |- | ||
| [[REVEAL Trial]] | | [[REVEAL Trial]] | ||
|- | |||
| REVEAL HPS-3 TIMI-55 trial | |||
|- | |- | ||
|} | |} |
Revision as of 12:17, 20 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
High density lipoprotein landmark trials On the Web |
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
ACCELERATE Trial |
Dal-OUTCOMES Trial |
Dal-VESSEL Trial |
Dal-PLAQUE Trial |
DEFINE Trial |
ILLUMINATE Trial |
ILLUSTRATE Trial |
REVEAL Trial |
REVEAL HPS-3 TIMI-55 trial |
Niacin
AIM-HIGH Trial |
ARBITER 2 Trial |
ARBITER 3 Trial |
ARBITER 6-HALTS Trial |
CLAS Trial |
HATS Trial |
Oxford Niaspan Study |
Fibrate
VA-HIT Trial |
BECAIT Trial |
BIP Trial |
Statin
ASTEROID Trial |
SATURN Trial |
4S Trial |
CORONA Trial |
Multiple Lipid Lowering Drugs
HARP Study |
AFREGS Trial |